Denosumab & Abaloparatide

Amgen Announces Positive TopLine Results From Phase 3 Study Of Prolia Denosumab In Patients Receiving Glucocorticoid Therapy

 Amgen Logo.

YOU ARE NOW LEAVING AMGEN’S WEB SITE.…
amgen.com

Anabolic Abaloparatide Looks Promising in Osteoporosis Fracture Prevention

In addition to sclerostin inhibitor (romosozumab), another new agent (abaloparatide) is also in phase III trials. Abaloparatide is an anabolic, parathyroid hormone-related protein (PTHrP) analog drug being developed by Radius Health  for the osteoposis market and is now in phase III clinical trials…
rheumnow.com